ReviewBlood2019
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
Review in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.Blood advances · 2026Article
- Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.EJHaem · 2025Article
- Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib.Blood neoplasia · 2025Article
- Article
- Review
- Article
- Exploring the molecular mechanisms between lymphoma and myelofibrosis.American journal of translational research · 2024Review
- Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.Clinical and experimental medicine · 2023Review
- [Management of inflammatory rheumatic diseases during and after malignancies].Zeitschrift fur Rheumatologie · 2022Article
- Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.International journal of hematology · 2022Review
- Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2Journal of clinical and experimental hematopathology : JCEH · 2021Article
- Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.Hematology/oncology clinics of North America · 2021Review
- JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.HemaSphere · 2020Review
- Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.JCO oncology practice · 2020Review
- Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.Blood reviews · 2020Review
- Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.Leukemia & lymphoma · 2020Article
- Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.Blood advances · 2019Article
- The Rationale for Immunotherapy in Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2019Review
- Standard care and investigational drugs in the treatment of myelofibrosis.Drugs in context · 2019Review
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.Frontiers in oncology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.